Leonardo Gomes Pereira

Dr. Leonardo Gomes Pereira

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2023 in Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology
Verified
Journal Article
Closed access
IMIllana Kemmerich Martins
Illana Kemmerich Martins
Leonardo Gomes PereiraLeonardo Gomes Pereira
Leonardo Gomes Pereira
MNMauro Eugênio Medina Nunes
Mauro Eugênio Medina Nunes
ALAndressa Rubim Lopes
Andressa Rubim Lopes
LLLuana Paganotto Leandro
Luana Paganotto Leandro
TPThaís Posser
Thaís Posser

1 August 2022 in Current Neuropharmacology
Verified
Journal Article
Open access
PDF file
Leonardo Gomes PereiraLeonardo Gomes Pereira
Leonardo Gomes Pereira
PRPatrícia Rodrigues
Patrícia Rodrigues
FVFernanda Tibolla Viero
Fernanda Tibolla Viero
JFJulia Maria Frare
Julia Maria Frare
LRLuís Guilherme Ramanzini
Luís Guilherme Ramanzini
GTGabriela Trevisan
Gabriela Trevisan
: Multiple sclerosis (MS) is a chronic neurodegenerative, inflammatory, and autoimmune disease characterised by the demyelination of the central nervous system. One of the main approaches for treating MS is the use of disease-modifying therapies (DMTs). Among the DMTs are interferons (IFNs), which are cytokines responsible for controlling the activity of the immune system while exerting immunomodulatory, antiviral, and antiproliferative activities. IFN-beta (IFN-β) is the first-choice drug used to treat relapsing-remitting MS. However, the administration of IFN-β causes numerous painful adverse effects, resulting in lower adherence to the treatment. Therefore, this study aimed to investigate the headache and flu-like pain symptoms observed after IFNβ injection in MS patients using a systematic review and meta-analysis of randomised controlled trials. A total of 2370 articles were identified through research databases. Nine articles were included (three involving IFNβ-1b and six involving IFNβ-1a). All studies included in the meta-analysis had a low risk of bias. The odds ratio of headache and flu-like pain symptoms increased in MS patients treated with IFN-β. Thus, the adverse effects of headache and flu-like pain symptoms appear to be linked to IFN-β treatment in MS. The protocol of the study was registered in the Prospective International Registry of Systematic Reviews (registration number CRD42021227593).

1 January 2024 in Current Neuropharmacology
Verified
Journal Article
Closed access
PDF file
SKSabrina Qader Kudsi
Sabrina Qader Kudsi
FVFernanda Tibolla Viero
Fernanda Tibolla Viero
Leonardo Gomes PereiraLeonardo Gomes Pereira
Leonardo Gomes Pereira
GTGabriela Trevisan
Gabriela Trevisan
Background: Musculoskeletal pain is a condition that affects bones, muscles, and tendons and is present in various diseases and/or clinical conditions. This type of pain represents a growing problem with enormous socioeconomic impacts, highlighting the importance of developing treatments tailored to the patient's needs. TRP is a large family of non-selective cation channels involved in pain perception. Vanilloid (TRPV1 and TRPV4), ankyrin (TRPA1), and melastatin (TRPM8) are involved in physiological functions, including nociception, mediation of neuropeptide release, heat/cold sensing, and mechanical sensation. Objective: In this context, we provide an updated view of the most studied preclinical models of muscle hyperalgesia and the role of transient receptor potential (TRP) in these models. Methods: This review describes preclinical models of muscle hyperalgesia induced by intramuscular administration of algogenic substances and/or induction of muscle damage by physical exercise in the masseter, gastrocnemius, and tibial muscles. Results: The participation of TRPV1, TRPA1, and TRPV4 in different models of musculoskeletal pain was evaluated using pharmacological and genetic tools. All the studies detected the antinociceptive effect of respective antagonists or reduced nociception in knockout mice. Conclusion: Hence, TRPV1, TRPV4, and TRPA1 blockers could potentially be utilized in the future for inducing analgesia in muscle hypersensitivity pathologies.


25 June 2024 in Ageing Research Reviews
Verified
Journal Article
Closed access
Leonardo Gomes PereiraLeonardo Gomes Pereira
Leonardo Gomes Pereira
PRPatrícia Rodrigues
Patrícia Rodrigues
FVFernanda Tibolla Viero
Fernanda Tibolla Viero
SKSabrina Qader Kudsi
Sabrina Qader Kudsi
JFJulia Maria Frare
Julia Maria Frare
GTGabriela Trevisan
Gabriela Trevisan

29 December 2024 in European Journal of Pharmacology
Verified
Journal Article
Closed access
FVFernanda Tibolla Viero
Fernanda Tibolla Viero
IMIuri Felix Morais
Iuri Felix Morais
PRPatrícia Rodrigues
Patrícia Rodrigues
SKSabrina Qader Kudsi
Sabrina Qader Kudsi
Leonardo Gomes PereiraLeonardo Gomes Pereira
Leonardo Gomes Pereira
GTGabriela Trevisan
Gabriela Trevisan